BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 28123081)

  • 1. Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.
    Naia L; Cunha-Oliveira T; Rodrigues J; Rosenstock TR; Oliveira A; Ribeiro M; Carmo C; Oliveira-Sousa SI; Duarte AI; Hayden MR; Rego AC
    J Neurosci; 2017 Mar; 37(10):2776-2794. PubMed ID: 28123081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.
    Naia L; Ribeiro M; Rodrigues J; Duarte AI; Lopes C; Rosenstock TR; Hayden MR; Rego AC
    Neuropeptides; 2016 Aug; 58():73-81. PubMed ID: 26876526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors.
    Oliveira JM; Chen S; Almeida S; Riley R; Gonçalves J; Oliveira CR; Hayden MR; Nicholls DG; Ellerby LM; Rego AC
    J Neurosci; 2006 Oct; 26(43):11174-86. PubMed ID: 17065457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer.
    Nunes-Xavier CE; Mingo J; Emaldi M; Flem-Karlsen K; Mælandsmo GM; Fodstad Ø; Llarena R; López JI; Pulido R
    Front Oncol; 2022; 12():873516. PubMed ID: 35692804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington's disease knock-in striatal cells.
    Ribeiro M; Rosenstock TR; Oliveira AM; Oliveira CR; Rego AC
    Free Radic Biol Med; 2014 Sep; 74():129-44. PubMed ID: 24992836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenyl butyrate inhibits pyruvate dehydrogenase kinase 1 and contributes to its anti-cancer effect.
    Zhang W; Zhang SL; Hu X; Tam KY
    Eur J Pharm Sci; 2017 Dec; 110():93-100. PubMed ID: 28450154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Mitochondrial-Based Protective Effects of Resveratrol and Nicotinamide in Huntington's Disease Models.
    Naia L; Rosenstock TR; Oliveira AM; Oliveira-Sousa SI; Caldeira GL; Carmo C; Laço MN; Hayden MR; Oliveira CR; Rego AC
    Mol Neurobiol; 2017 Sep; 54(7):5385-5399. PubMed ID: 27590140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic
    Cenigaonandia-Campillo A; Serna-Blasco R; Gómez-Ocabo L; Solanes-Casado S; Baños-Herraiz N; Puerto-Nevado LD; Cañas JA; Aceñero MJ; García-Foncillas J; Aguilera Ó
    Theranostics; 2021; 11(8):3595-3606. PubMed ID: 33664850
    [No Abstract]   [Full Text] [Related]  

  • 10. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
    Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM
    Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative metabolism in YAC128 mouse model of Huntington's disease.
    Hamilton J; Pellman JJ; Brustovetsky T; Harris RA; Brustovetsky N
    Hum Mol Genet; 2015 Sep; 24(17):4862-78. PubMed ID: 26041817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
    Ferrante RJ; Kubilus JK; Lee J; Ryu H; Beesen A; Zucker B; Smith K; Kowall NW; Ratan RR; Luthi-Carter R; Hersch SM
    J Neurosci; 2003 Oct; 23(28):9418-27. PubMed ID: 14561870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
    Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
    Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-Jun N-terminal kinase regulates mitochondrial bioenergetics by modulating pyruvate dehydrogenase activity in primary cortical neurons.
    Zhou Q; Lam PY; Han D; Cadenas E
    J Neurochem; 2008 Jan; 104(2):325-35. PubMed ID: 17949412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites.
    Kolobova E; Tuganova A; Boulatnikov I; Popov KM
    Biochem J; 2001 Aug; 358(Pt 1):69-77. PubMed ID: 11485553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic Connection of Inflammatory Pain: Pivotal Role of a Pyruvate Dehydrogenase Kinase-Pyruvate Dehydrogenase-Lactic Acid Axis.
    Jha MK; Song GJ; Lee MG; Jeoung NH; Go Y; Harris RA; Park DH; Kook H; Lee IK; Suk K
    J Neurosci; 2015 Oct; 35(42):14353-69. PubMed ID: 26490872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged hypoxia decreases nuclear pyruvate dehydrogenase complex and regulates the gene expression.
    Eguchi K; Nakayama K
    Biochem Biophys Res Commun; 2019 Nov; 520(1):128-135. PubMed ID: 31582221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease.
    Niatsetskaya Z; Basso M; Speer RE; McConoughey SJ; Coppola G; Ma TC; Ratan RR
    Antioxid Redox Signal; 2010 Apr; 12(4):435-43. PubMed ID: 19659431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
    Jia H; Pallos J; Jacques V; Lau A; Tang B; Cooper A; Syed A; Purcell J; Chen Y; Sharma S; Sangrey GR; Darnell SB; Plasterer H; Sadri-Vakili G; Gottesfeld JM; Thompson LM; Rusche JR; Marsh JL; Thomas EA
    Neurobiol Dis; 2012 May; 46(2):351-61. PubMed ID: 22590724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel proteomic changes in brain mitochondria provide insights into mitochondrial dysfunction in mouse models of Huntington's disease.
    Agrawal S; Fox JH
    Mitochondrion; 2019 Jul; 47():318-329. PubMed ID: 30902619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.